Executive Management Team
Randal J. Kirk, Chairman and Chief Executive Officer
R.J. Kirk is Chairman and Chief Executive Officer of Intrexon, a leading synthetic biology technology company. Mr. Kirk was named Chairman in February 2008 and was later appointed Chief Executive Officer in April 2009.
Mr. Kirk serves on the Board of Directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) as well as the Board of Directors of ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). In addition, Mr. Kirk is Founder, Senior Managing Director and Chief Executive Officer of Third Security, LLC, an investment management firm.
Prior to Intrexon, Mr. Kirk served on the Board of Directors of Clinical Data, Inc. starting in September 2002. In December 2004 he became Chairman of the Board of Directors and served in that capacity until the NASDAQ-traded company was acquired by Forest Laboratories, Inc. in April 2011.
Mr. Kirk was also Chairman of the Board of New River Pharmaceuticals Inc., a specialty biopharmaceutical company he founded in 1996. New River Pharmaceuticals traded on NASDAQ until its acquisition by Shire plc on April 18, 2007.
From February 2000 to May 2002, Mr. Kirk served as a member of the Board of Directors of Scios, Inc. a biopharmaceutical company that traded on NASDAQ prior to its acquisition by Johnson & Johnson on April 29, 2003.
Mr. Kirk received a B.A. in Business from Radford University and a J.D. from the University of Virginia. He began his professional career in the private practice of law.
Thomas D. Reed, Ph.D., Founder and Chief Science Officer
Dr. Reed is a molecular geneticist with over twenty years of experience in recombinant DNA technology. He has developed sophisticated transgenic model systems for studying the role of gene products in neuronal, cardiovascular, and cancer systems.
Dr. Reed has published numerous peer-reviewed articles in the fields of subcellular modulation, gene regulation and cardiac function and is an inventor on numerous patents.
Dr. Reed co-founded Intrexon in 1998. He received his B.S. in Genetics from the University of California-Davis and then completed his M.S. at Wright State University in Biological Science. Dr. Reed received his Ph.D. from the University of Cincinnati in Molecular and Developmental Biology.
Krish S. Krishnan, Chief Operating Officer
Mr. Krishnan brings many years of experience in the life sciences industry, having held key executive roles at several companies including, most notably, his tenure as Chief Financial Officer, Chief Operating Officer, and board member of New River Pharmaceuticals, Inc. (previously traded on NASDAQ prior to its acquisition by Shire plc in 2007).
Previously, he served as a Senior Managing Director of Third Security, LLC between 2001 and 2008 and as a board member of Biotie Therapies Oyj (BTH1V:Helsinki) between 2008 and 2009.
Mr. Krishnan started his career as an engineer with E.I. Dupont de Nemours in Wilmington, Delaware. He received a B.S. in Mechanical Engineering from the Indian Institute of Technology, a M.S. in Engineering from UT, Ohio, and an M.B.A. in Finance from The Wharton School at the University of Pennsylvania.
Don Lehr, Chief Legal Officer
Mr. Lehr has broad experience in the areas of corporate, securities, and general business law. Prior to joining Intrexon, he was at Hogan Lovells LLP (previously Hogan & Hartson, L.L.P.) in Baltimore, Maryland. While at Hogan, his practice included the representation of privately and publicly held corporations across many industries, including biotechnology, pharmaceuticals, healthcare, software, technology, and manufacturing.
Prior to his time at Hogan, Mr. Lehr served as a judicial clerk for the Honorable Irma S. Raker of the Court of Appeals of Maryland.
Mr. Lehr received a B.A. from Swarthmore College, completed post graduate study in Political Science at Johns Hopkins University, and received his J.D. from the University of Maryland School of Law.
Rick Sterling, Chief Financial Officer
Mr. Sterling joined Intrexon in 2007 as the Chief Financial Officer. Prior to joining Intrexon, he was with KPMG where he worked in the audit practice for over 17 years, with a client base primarily in the health, technology and manufacturing industries.
Mr. Sterling’s experience includes serving clients in both the private and public sector, including significant experience with SEC filings and Sarbanes-Oxley compliance.
He has a B.S. in Accounting and Finance from Virginia Tech and is a licensed CPA.
Samuel Broder, M.D., Executive Vice President, Scientific and Public Affairs
Dr. Broder brings more than 30 years of internal medicine and oncology experience to Intrexon. Most notably, Dr. Broder was Director of the National Cancer Institute (NCI) during the Reagan administration, a position he held for six years.
Before joining Intrexon in 2012, Dr. Broder was the Executive Vice President for Medical Affairs and Chief Medical Officer at Celera Corporation, now a division of Quest Diagnostics, where he helped advance the human genome project. While directing NCI, he oversaw the development of many anti-cancer therapeutic agents, helped launch a number of large-scale clinical trials related to the prevention, diagnosis and treatment of cancer, and launched the highly successful SPORE Program.
Dr. Broder also played a major role in developing the first three FDA-approved AIDS treatments. He has served as a board member and as a consultant for numerous pharmaceutical and biotech companies in the U.S. and abroad. Dr. Broder has authored or co-authored more than 340 scientific publications, holds multiple patents, and was elected to the Institute of Medicine of the National Academy of Sciences in 1993. Dr. Broder earned his M.D. from the University of Michigan Medical School in Ann Arbor in 1970.
Darryl Webster, Senior Vice President, Intellectual Property
Mr. Webster has over 25 years of legal experience. During his law firm experience and 20 plus years of corporate IP practice, he has worked in scientific areas that match each of the markets Intrexon is targeting.
Prior to joining Intrexon, Mr. Webster was Senior Patent Counsel at Wyeth Pharmaceuticals, Inc. (now Pfizer Inc.). During his sixteen years at Wyeth, he was the lead patent counsel for several key products and areas including a $6B biological, the Asia Pacific Region, and the Wyeth Nutrition business.
Before his work at Wyeth, he worked for more than four years in the core chemical and biochemical areas at AlliedSignal Inc., now Honeywell International Inc. Mr. Webster has Bachelors' degrees in Chemistry (Biological Specialization) and Economics from Duke University and his J.D. from the University of Maryland School of Law.
Suma M. Krishnan, Senior Vice President, Product Development
Mrs. Krishnan has been with Intrexon since 2012. From 2009 to 2011, Mrs. Krishnan served as Senior Vice President of Product Development at Pinnacle Pharmaceuticals, Inc. From 2007 to 2009, she served as Chief Financial Officer of Light Matters Foundation. Previously, Mrs. Krishnan was Vice President, Product Development at New River Pharmaceuticals Inc. from September 2002 until its acquisition by Shire plc in April 2007.
Mrs. Krishnan has 22 years’ experience in drug development. Prior to serving at New River Pharmaceuticals Inc., Mrs. Krishnan served in the following capacities: Director, Regulatory Affairs at Shire Pharmaceuticals, Inc., a specialty pharmaceutical company; Senior Project Manager at Pfizer, Inc., a multi-national pharmaceutical company; and a consultant at the Weinberg Group, a pharmaceutical and environmental consulting firm.
Mrs. Krishnan began her career as a discovery scientist for Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, a multi-national pharmaceutical company, in May 1991. Mrs. Krishnan received an M.S. in Organic Chemistry from Villanova University, an M.B.A. from Institute of Management and Research (India) and an undergraduate degree in Organic Chemistry from Ferguson University (India).